Table 5.

Characteristics of 55 patients with parainfluenza virus-3 lower respiratory tract infections, according to ribavirin therapy

Characteristic
Treated with ribavirin (n = 31)No ribavirin (n = 24)
Underlying disease   
 Acute leukemia 11  (35%) 10  (42%)  
 CML 8  (26%) 8  (33%) 
 HD/MM/NHL 6  (19%) 4  (17%)  
 MDS 3  (10%) 0  (0%)  
 Other 3  (10%) 2  (8%)  
Donor type   
 Matched related 10  (32%) 8  (33%) 
 Mismatched/unrelated 16  (52%) 11  (46%) 
 Autologous 5  (16%) 5  (21%)  
Acute GVHD5-150   
 Grade 0-II 16  (62%) 10  (56%) 
 Grade III-IV 10  (38%) 8  (44%)  
Engrafted at diagnosis?   
 Yes 21  (68%) 19  (79%) 
 No 10  (32%) 5  (21%)  
Ventilated at diagnosis?   
 Yes 4  (13%) 1  (4%)  
 No 27  (87%) 23  (96%)  
Oxygen requirement at diagnosis?   
 Yes 15  (48%) 9  (38%) 
 No 16  (52%) 15  (62%) 
Characteristic
Treated with ribavirin (n = 31)No ribavirin (n = 24)
Underlying disease   
 Acute leukemia 11  (35%) 10  (42%)  
 CML 8  (26%) 8  (33%) 
 HD/MM/NHL 6  (19%) 4  (17%)  
 MDS 3  (10%) 0  (0%)  
 Other 3  (10%) 2  (8%)  
Donor type   
 Matched related 10  (32%) 8  (33%) 
 Mismatched/unrelated 16  (52%) 11  (46%) 
 Autologous 5  (16%) 5  (21%)  
Acute GVHD5-150   
 Grade 0-II 16  (62%) 10  (56%) 
 Grade III-IV 10  (38%) 8  (44%)  
Engrafted at diagnosis?   
 Yes 21  (68%) 19  (79%) 
 No 10  (32%) 5  (21%)  
Ventilated at diagnosis?   
 Yes 4  (13%) 1  (4%)  
 No 27  (87%) 23  (96%)  
Oxygen requirement at diagnosis?   
 Yes 15  (48%) 9  (38%) 
 No 16  (52%) 15  (62%) 

CML indicates chronic myelogenous leukemia; HD, Hodgkin disease; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; MDS, myelodysplasia; GVHD, graft-versus-host disease.

F5-150

Allogeneic recipients only.

Close Modal

or Create an Account

Close Modal
Close Modal